Lipodystrophies, heterogeneous acquired or inherited disorders characterized by the
selective loss of adipose tissue, predispose affected patients to insulin resistance and its …

Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors
(statins), are widely used in the treatment and prevention of atherosclerotic disease. The …

Metabolic complications such as dyslipidemia, insulin resistance, and altered fat distribution
(loss of subcutaneous fat and relatively increased central fat) are common in adults infected …

Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …

Statin-related myopathy is a clinically important cause of statin intolerance and
discontinuation. The spectrum of statin-related myopathy ranges from common but clinically …

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used for the treatment of hypercholesterolemia. Their efficacy in preventing cardiovascular …

Cardiovascular disease, and particularly coronary heart disease, is an emerging area of
concern in the HIV population. Since the advent of efficient antiretroviral therapies and the …

Dyslipidemia is a common problem affecting HIV-infected patients receiving antiretroviral
therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have …

Transporters play an important role in the processes of drug absorption, distribution and
excretion. In this review, we have focused on the involvement of transporters in drug …

Lipodystrophy is a medical condition characterized by complete or partial loss of adipose
tissue. Not infrequently, lipodystrophy occurs in combination with pathological accumulation …